In this week’s issue:
- Alex’s Lemonade Stand Foundation – ‘A’ Award Grants in Pediatric Oncology Research for young scientists (reminder)
- Faculty of Medicine – Spring Start Up Funds (reminder)
- Western Economic Diversification Canada – Western Diversification Program, Call for Proposals(reminder)
- The International Society for Heart & Lung Transplantation – ISHLT/Bayer Pulmonary Hypertension Research Grant Award
- Canadian Physician Health Institute – Special Project Fund ((1 attachment)
- Prostate Cancer Foundation in Collaboration with the Marcus Foundation – Call for Letter of Intent – “Intravenous Vitamin C Therapy for Prostate Cancer Patients”(reminder)
- Society for the Advancement of Blood Management – Haemonetics Research Starter Grant
- Fahs-Beck Fund for Research and Experimentation – Faculty/Post-Doctoral Grant Program (Fahs-Beck Fellows)
Awards and Honours:
- National Foundation for Cancer Research – 2015 Szent-Györgyi Prize for Progress in Cancer Research
Deadline: May 23, 2014
Alex’s Lemonade Stand Foundation, a not-for-profit foundation that evolved from a young cancer patient’s front-yard lemonade stand to a national foundation for childhood cancer, awards grants designed to fill critical gaps in pediatric cancer research.
The foundation’s “A” Award Grants provides a $450,000 grant over three years to young scientists who want to jump-start their careers in pediatric oncology research. To be eligible for the award, applicants must have their M.D., Ph.D., or dual M.D./Ph.D., and must not have achieved an appointment higher than assistant professor. M.D. or M.D./Ph.D. candidates must be no more than six years from finishing a three-year fellowship.
The ideal candidate has an original project that currently is not being funded. Demonstration of outstanding mentorship and a future commitment to pediatric cancer investigation are critical components of a successful application.
For additional details, please visit the ALSF website.
Deadline: May 30, 2014
The Faculty of Medicine has funds available for two awards of $5000. Applicants must be in the first two years of a full-time appointment as Assistant Professor or higher, or a Clinical faculty appointment as Clinical Assistant Professor or higher, in the Faculty of Medicine at the University of British Columbia. Previous awardees of UBC Faculty of Medicine Spring Start Up Funds, and applicants who have received $200,000 or more in Start Up Funds are ineligible.
The funds can be used for the following: Research equipment, research supplies and/or research services (e.g. cost recovery payments to core equipment) and research support salaries (e.g. technical personnel).
Please visit our website for more information.
Deadline: May 30, 2014
The Western Diversification Program (WDP) is the main program through which Western Economic Diversification Canada (WD) makes strategic investments in initiatives that enhance and strengthen the economy of Western Canada. The Call for Proposals (CFP) process is a fair, open, transparent and widely accepted business process whereby interested parties develop project proposals and apply for funding. Projects involving all industry sectors will be considered.
WD has focused its priorities on: Innovation; Industrial and Technological Benefits, Trade and Investment, Economic Growth Acceleration Opportunities for Aboriginal Peoples; and Skills Development and Training. WD supports projects that are aligned with its mandate and meet its priorities.
For additional details, please visit the WD website.
Deadline: June 2, 2014
The International Society for Heart and Lung Transplantation is a multidisciplinary professional organization dedicated to improving the care of patients with advanced heart or lung disease via research, education, and advocacy.
ISHLT is accepting applications for the 2014 ISHLT/Bayer Pulmonary Hypertension Research Grant, an annual award aimed at furthering the scientific understanding of pulmonary hypertension, with the ultimate goal of improving patient’s lives. One $100,000 grant ($50,000 per year for two years) will be awarded to an ISHLT member for a research project that investigates a relevant clinical or translational science question in pulmonary hypertension (PH), irrespective of the PH subtype.
For further details, please visit the ISHLT website.
Deadline: June 9, 2014
The Canadian Physician Health Institute is a national program focused on promoting physician mental health and wellness. Created by the Canadian Medical Association and the Canadian Medical Foundation, the Institute works with and through partners, to share information and build knowledge around the issues related to physician mental health.
CPHI is now accepting submissions to the Special Projects Fund. The fund is designed to support the promotion of physician health and wellness at the national level. CPHI encourages submissions from a wide range of proponents, including researchers, students, advocacy organizations, practicing physicians, residents, PhD students, educators, physician health programs and others. There is $145,000 available to be awarded through a peer-review process. Projects should address at least one of the following four themes: Education and training in physician health at undergraduate and post-graduate medical education level; Elimination of stigma associated with physician illness, impairment, or disability; Professionalism and disruptive behavior; or All other themes related to primary prevention.
Prostate Cancer Foundation in Collaboration with the Marcus Foundation – Call for Letter of Intent – “Intravenous Vitamin C Therapy for Prostate Cancer Patients”
Deadline for LOI: June 30, 2014
The Prostate Cancer Foundation (PCF) is a global philanthropic foundation committed to funding basic, translational, and clinical research that will lead to better treatment for prostate cancer patients.
PCF, in collaboration with the Marcus Foundation, is currently soliciting a call for a Letter of Intent (LOI) to apply for a 1-year, $100K Pilot Award for a project that will interrogate the mechanisms and potential efficacy of vitamin C therapy in prostate cancer (PCa) patients and mitigation of chemotherapy-associated toxicity.
High dose intravenous vitamin C therapy has long been suggested to generate tumor cell-specific cytotoxic effects but clinical trials have not definitively proven efficacy in cancer patients. Furthermore, the mechanisms by which vitamin C exerts tumor cell cytotoxicity were unclear. A recent paper by Ma et al. (SciTransl Med. 2014 Feb 5;6(222):222ra18) demonstrated that intravenous vitamin C induced death of ovarian cancer cells through activation of DNA damage and ATP depletion leading to mTOR inhibition via activation of AMPK. In addition, this study demonstrated therapeutic synergy between high dose vitamin C and chemotherapy in inhibiting ovarian cancer growth in xenograft models. Activation of AMPK has pleotropic effects in suppressing PCa growth and is an ongoing area of investigation as a treatment strategy for advanced PCa. Thus, high dose, intravenous vitamin C administration may be applicable to the treatment of advanced PCa via these or other mechanisms.
We are particularly interested in the observation by Ma, et al. that the side effects of chemotherapy were mitigated by intravenous vitamin C in a model of ovarian cancer. This should be considered for the design of prostate cancer investigations.
PCF will fund a one-year (individual) project that will investigate the mechanisms and potential for intravenous vitamin C therapy in the treatment of advanced prostate cancer and mitigation of chemotherapy-associated toxicity. Investigators representing non-profit academic research centers worldwide are eligible to apply. Investigators from for-profit companies and government-sponsored institutions, i.e. NIHI, are ineligible.
To apply for this award, please submit a 2-page LOI that contains the following: Research Strategy and Objectives; Impact; and Personnel. The LOI should include your name, email address and phone number at the top of the page. Please email a PDF of the LOI to firstname.lastname@example.org. A select number of applicants will be invited by PCF to submit full five-page applications for this award.
Deadline: July 1, 2014
The SABM-Haemonetics Research Starter Grant is intended to advance the field of patient blood management by supporting a young investigator who intends to study methods of promoting blood conservation. This one-year, $20,000 grant provides starter funding to further scientific inquiry and clinical knowledge in the field of patient blood management. Preference will be given to junior faculty who will be advised by an experienced mentor. It is anticipated that the funded study will generate results that can be used as pilot data or preliminary findings to support future grant applications focused on methods to improve blood management and to promote blood conservation. It is expected that all applicants will be members of SABM, or will become members of SABM for at least one year.
For additional details, please visit the SABM website.
Deadline: November 1, 2014
Grants of up to $20,000 are available to help support the research of faculty members or post-doctoral researchers affiliated with non-profit human service organizations in the United States and Canada. Areas of interest to the Fund are: studies to develop, refine, evaluate, or disseminate innovative interventions designed to prevent or ameliorate major social, psychological, behavioral or public health problems affecting children, adults, couples, families, or communities, or studies that have the potential for adding significantly to knowledge about such problems. The research for which funding is requested must focus on the United States or Canada or on a comparison between the United States or Canada and one or more other countries.
For more details, please visit the Fahs-Beck website.
AWARDS AND HONOURS:
Deadline: September 30, 2014
The National Foundation for Cancer Research is accepting nominations for the 2015 Szent-Györgyi Prize for Progress in Cancer Research.
The annual prize, named in honor of Albert Szent-Györgyi, Nobel Laureate and co-founder of NFCR, is awarded to an outstanding researcher whose scientific achievements have expanded our understanding of cancer and whose discoveries have made possible new approaches to preventing, diagnosing, and/or treating cancer.
Nominations may be made by individuals from the research community, industry, government, and other organizations that are sufficiently familiar with the research accomplishments and contributions of the nominee. Self-nominations will not be accepted. Candidates must have made an original discovery or breakthrough in scientific understanding that has led to better prevention, earlier diagnosis, or new treatments for patients with cancer.
The prize recipient will be honored at a formal dinner and award ceremony and will receive a $25,000 cash prize. In addition, the recipient will lead the next Szent-Györgyi prize committee as honorary chair.
Please visit the NFCR website for further information and nomination details.